-
Pyxis Oncology (PYXS) files $350M mixed shelf
-
Pyxis Oncology Inc. (PYXS) PT Raised to $8 at Stephens
-
Pyxis Oncology Inc. (PYXS) PT Raised to $7 at Guggenheim
-
Pyxis Oncology, Inc. (PYXS) Misses Q3 EPS by 1c
-
Guggenheim Starts Pyxis Oncology Inc. (PYXS) at Buy
-
Pyxis Oncology, Inc. (PYXS) Tops Q2 EPS by 4c
-
Pyxis Oncology, Inc. (PYXS) Misses Q1 EPS by 2c
-
Pyxis Oncology (PYXS) Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin
-
Pyxis Oncology, Inc. (PYXS) Misses Q4 EPS by 100c
-
Pyxis Oncology Inc. (PYXS) PT Lowered to $6 at Jefferies
-
Pyxis Oncology (PYXS) Granted FDA Fast Track Designation for PYX-201
-
Pyxis Oncology (PYXS) Initiates New PYX-201 Combination Trial
-
Pyxis Oncology Inc. (PYXS) PT Lowered to $5 at H.C. Wainwright
-
Pyxis Oncology Inc. (PYXS) PT Lowered to $8; RBC Capital: 'We Would Be Buyers into 2025 Data'
-
Pyxis Oncology (PYXS) Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
-
Pyxis Oncology Inc. (PYXS) PT Raised to $10 at RBC Capital
-
Pyxis Oncology (PYXS) Reports Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
-
Pyxis Oncology (PYXS) call put ratio 1 call to 1 put into data
-
Pyxis Oncology (PYXS) call put ratio 1.3 calls to 1 put into investor event
-
Pyxis Oncology (PYXS) call put ratio 1.6 calls to 1 put into investor event
-
Pyxis Oncology, Inc. (PYXS) Misses Q3 EPS by 3c
-
Pyxis Oncology (PYXS) call put ratio 2.9 calls to 1 put into data
-
H.C. Wainwright Reiterates Buy Rating on Pyxis Oncology Inc. (PYXS)
-
Pyxis Oncology, Inc. (PYXS) Tops Q2 EPS by 5c
-
Stifel Starts Pyxis Oncology Inc. (PYXS) at Buy
-
RBC Capital Reiterates Outperform Rating on Pyxis Oncology Inc. (PYXS)
-
Pyxis Oncology (PYXS) Appoints Michael A. Metzger to its Board

